ConvaTec is said to weighing a sale or even an initial public offering next year, even as interest in the tax inversion such a deal would bring mounts from players including C.R. Bard (NYSE:BCR), CareFusion (NYSE:CFN) and 3M Cos. (NYSE:MMM), Reuters reported.
ConvaTec, which is domiciled in Luxembourg, was bought Bristol-Myers Squibb for $4.1 billion in 2011 by private equity firms Nordic Capital and Avista Capital Partners, with 3M also in the running for a spell.
Hey, check out all the research scientist jobs. Post your resume today!
